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Pierre Ernst1,2,3*, Christel Renoux1, Sophie Dell’Aniello1 and Samy Suissa1,3Abstract
Background: Patients with Parkinson’s disease have an elevated risk of pneumonia and randomized trials suggest
that this risk may be increased with the dopamine agonist pramipexole. It is uncertain whether pramipexole or
other dopamine agonists increase the risk of pneumonia.
Methods: We used the United Kingdom’s General Practice Research Database (GPRD) to identify users of
anti-parkinsonian drugs, 40–89 years of age, between 1997 and 2009. Using a nested case–control approach, all
incident cases hospitalised for pneumonia were matched with up to ten controls selected among the cohort
members. Rate ratios (RR) and 95% confidence intervals (CI) of pneumonia associated with current use of dopamine
agonists were estimated using conditional logistic regression, adjusted for covariates.
Results: The cohort included 13,183 users of anti-parkinsonian drugs, with 1,835 newly diagnosed with pneumonia
during follow-up (rate 40.9 per 1,000 per year). The rate of pneumonia was not increased with the current use of
pramipexole (RR 0.76; 95% CI: 0.57-1.02), compared with no use. The use of pramipexole was not associated with an
increased rate of pneumonia when compared with all other dopamine agonists collectively (RR 0.85; 95% CI:
0.62-1.17).
Conclusions: The use of pramipexole does not appear to increase the risk of pneumonia.
Keywords: Anti-parkinsonian drugs, Drug safety, Parkinson’s disease, Restless leg syndrome, Observational studyBackground
Parkinson’s disease generally affects the elderly with a
prevalence of around 2% among the northwestern Euro-
pean population over 65 years of age [1,2]. Dopamine ago-
nists have become first-line agents for the symptomatic
treatment of Parkinson’s disease, but are also used in other
conditions such as restless legs syndrome. Parkinson’s dis-
ease has been associated with significant increases in
deaths from pneumonia and aspiration pneumonia, pos-
sibly resulting from the combination of chronic
immobilization and swallowing impairment [3-6].
Adverse events of pneumonia have been noted in asso-
ciation with pramipexole use in various trials conducted
by Boehringer-Ingelheim. The signal of a potential risk
of pneumonia arose in pooled data from 21 placebo con-
trolled randomized trials of pramipexole conducted in
Parkinson’s disease and restless legs syndrome [7]. The* Correspondence: pierre.ernst@mcgill.ca
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reproduction in any medium, provided the orpooled analysis, involving 3,662 patients on pramipexole
and 2,469 on placebo, observed a numerically increased
rate of adverse events of pneumonia (10.7 versus 3.6 per
1000 patient-years; rate ratio 2.5; 95%CI: 0.9- 7.0). The
adverse event data on pneumonia were, however, limited
by the small number of events in the clinical trials and
the fact that pneumonia was only one of several adverse
events reported in these trials, so that an association
could have been the result of chance. Moreover, no asso-
ciations between treatment for Parkinson’s disease and
pneumonia have been reported in the literature. Never-
theless, the possibility of an association between prami-
pexole and pneumonia remains and also raises the
question of an increase in the risk of pneumonia with
other dopamine agonists.
We therefore conducted a population-based cohort
study to assess whether the use of pramipexole and of
other dopamine agonists increases the risk of pneumonia.Methods
We used a population-based cohort study design with a
nested case–control analysis. This approach was necessaryd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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drug exposure.Data source
Data were obtained from the United Kingdom’s General
Practice Research Database (GPRD), which includes
computerized medical records of more than 10 million
patients from more than 500 general practices in the
United Kingdom. General practitioners, using standar-
dized recording of medical information, record data on
the patient’s demographic characteristics, symptoms, his-
tory, medical diagnoses, and drug prescriptions, as well
as details of referrals to specialists and hospitals. The
completeness and validity of the recorded information
on diagnoses and drug exposures, as checked on an on-
going basis by staff of the GPRD, have been shown in
several studies [8-10].
Recently, the GPRD gained approval to enable record
linkage of GPRD data with other healthcare databases
via the patient’s NHS (National Health Service) number,
sex, date of birth and Post Code. Specifically, the Hos-
pital Episode Statistics (HES) database records informa-
tion on all hospitalisations, including data on length of
stay, ward types, as well as extensive disease and proced-
ure coding. The linkage between the GPRD and the HES
databases applies to approximately half of the practices
contributing to the GPRD. The GPRD is the most vali-
dated of all databases used for drug safety and research
on the study of numerous diseases, including Parkinson’s
disease [11], and community-acquired pneumonia [12,13].Study population
The study base population included all users of anti-
parkinsonian drugs, registered with an up-to-standard
GPRD practice and who were 40 to 89 years of age be-
tween January 1, 1997 and June 30, 2009 (Figure 1). This
study period was selected to encompass the date prami-
pexole (Mirapexin) was approved (February 1998) and
subsequently entered the UK market. The drugs exam-
ined are the dopamine precursor levodopa, the
monoamine oxidase inhibitors selegiline and rasagiline,
and the dopamine agonists bromocriptine, cabergoline,
lisuride, pergolide, pramipexole, ropinirole, and rotigo-
tine. It is noteworthy to mention that these medications
are not only used for treatment of Parkinson’s disease,
but also given for the Parkinsonian syndrome, restless
legs syndrome, hyperprolactinemia and acromegaly.
Cohort entry was defined by the first prescription of
one of these drugs after the latest date among January 1,
1997, the date of the patient’s 40th birthday, and one
year after the date of the patient’s registration with the
practice, all after the up-to-standard date of the practice.
Patients who received any of these drugs in the yearbefore cohort entry were labeled as prevalent users,
while the others were considered new users. The follow-
up time of the cohort members ended at the time of the
occurrence of the first of the following events: a diagno-
sis of pneumonia, the 90th birthday, death, the end of
the patient’s registration with the practice or of the con-
tribution of data by the general practice, or the end of
the study period (June 30, 2009). Since the definition of
the pneumonia outcome required information from hos-
pitalizations, we excluded all subjects whose practice
was not linked to the HES database of hospitalization
records.Cases (endpoint)
Cases of pneumonia were defined by a first clinical diag-
nosis of severe community acquired pneumonia during
cohort follow-up identified by a hospitalization for pneu-
monia or acute lower respiratory infection identified using
ICD-10 codes. A record of a pneumonia or acute lower
respiratory infection diagnosis without hospitalization
was not included in the case definition. Patients were
not included as cases if pneumonia developed during
hospitalization (i.e., hospital-acquired pneumonia), so that
only diagnoses of pneumonia or acute lower respiratory
infection on the day of admission or the following day
were considered as eligible. The date of the first recorded
diagnosis was defined as the index date.Controls
Because of the time-varying nature of drug exposure, we
used a nested case–control approach to data analysis.
For each case, up to 10 controls per case were randomly
selected among the cohort members from the patients at
risk of developing pneumonia at the index date of the
case. Controls within the risk set were matched to the
case on the diagnosis (Parkinson’s disease, Parkinsonian
syndrome, restless legs syndrome, hyperprolactinemia
and acromegaly), age at index date (±5 years), sex, preva-
lent or new user status at cohort entry, and year of co-
hort entry. For 32 cases for which no controls could be
found, the matching criteria were widened for year of
cohort entry (±1 year) and age (±10 years), leaving four
cases that were excluded because no match could be
found. The controls were assigned the index date of the
case they were matched to.Exposure
All prescriptions for the dopamine agonists under study
were identified. These included the non-ergot derived
pramipexole, ropinirole, and rotigotine, and the ergot-
derived bromocriptine, cabergoline, lisuride, and pergo-
lide. For all cases and controls, current exposure to a
Figure 1 Flowchart describing the selection of the cohort of 13,183 users of anti-Parkinsonian drugs, 40–89 years of age, observed
between January 1, 1997 and June 30, 2009, identified from the United Kingdom’s General Practice Research Database (GPRD).
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after, or within 30 days prior to, the index date.
Covariates
To control for potential confounding, we identified sev-
eral factors in addition to the matching factors that in-
clude the drug indication, age, sex, new user status and
year of cohort entry. Thus, we also obtained data on use
of alcohol, smoking status, body mass index (BMI), as
well as co-morbidities associated with pneumonia, all
prior to cohort entry. In particular, these include chronic
obstructive pulmonary disease (COPD) including
chronic bronchitis, asthma, diabetes, cerebrovascular
disease, coronary heart disease, heart failure, rhythm ir-
regularity, cardiac valve condition, lung cancer, other
cancer, depression, motor neuron disease, bipolar dis-
order, psychosis, dementia, epilepsy, hypertension, renalfailure, anemia, peripheral edema, pneumonia hospita-
lized or not, all occurring any time prior to cohort entry.
In addition, other drugs used in this context including
the dopamine precursor levodopa, the monoamine
oxidase inhibitors selegiline and rasagiline, anticholin-
ergic drugs, the catechol-O-methyl transferase (COMT)
inhibitors and amantadine, were considered concurrently
to the drugs under study. The use of oral and inhaled corti-
costeroids, other respiratory medications, pneumococcal
and influenza vaccination, ACE-inhibitors, ARBs, diuretics,
NSAIDS, PPIs, barbiturates, anxiolytics, antipsychotics,
antidepressants, opiates, mood stabilizers, immunosuppres-
sants associated with an increased risk for pneumonia, was
identified in the year prior to index date. We adjusted for
antibiotics used in the year prior to the index date, but
excluded any prescriptions given in the 2 week before the
index date as it may be intended for early symptoms of
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duration of disease, calculated as the time between the date
of the first anti-parkinsonian drug and cohort entry.
Data analysis
The overall rate of pneumonia was computed for the co-
hort using the person-time of follow-up. Because of the
time-varying nature of anti-parkinsonian drug use, the
nested case–control approach to analysis was used to es-
timate the incidence rate ratios of pneumonia from odds
ratios calculated by conditional logistic regression, both
crude and adjusted for the potential confounders. For
the primary analysis, the incidence rate ratio was esti-
mated for current use of pramipexole compared with
the reference category of current use of other dopamine
agonists. For the secondary analysis, the effect of current
use of each dopamine agonist was estimated using a sin-
gle regression model where current use of each drug,
compared with non-current use of the drug, was
included as an independent factor. Missing confounder
data for smoking and BMI (15.6% and 26.2% respectively
in controls) was considered by creating a separate cat-
egory for the missing data.
Several sensitivity analyses were performed. First, we
restricted the analysis to the cohort of subjects for
whom the indication for treatment was Parkinson’s dis-
ease and to the sub-cohort with at least two prescrip-
tions for an anti-parkinsonian drug. Second, we varied
the 30-day definition of current use of the drugs by
using exposure time windows of 0, indicating prescrip-
tions ending at or after the index date, as well as 14, 60
and 90 days. Third, to examine the possibility of chan-
neling bias where the choice of medication might be
influenced by a history of pneumonia or prior use of
anti-parkinsonian medication, we carried out analyses
stratified by history of pneumonia prior to cohort entry
and by the type of anti-parkinsonian medication received
prior to the 180-day period before the index date. Finally,
we performed an analysis using a more restricted defin-
ition of pneumonia, that is, eliminating cases of pneumo-
nia due to aspiration of liquids or solids (ICD-10: J69),
lower respiratory infection without mention of pneumo-
nia, and either pneumonia or lower respiratory infection
with a concurrent diagnosis of heart failure.
The study protocol was approved by the Independent
Scientific Advisory Committee (ISAC) for the U.K. Med-
icines and Healthcare Products Regulatory Agency and
the Ethics Committee of the Jewish General Hospital.
All data used in this study was anonymized.
Results
The cohort included 13,183 patients treated with anti-
parkinsonian drugs, after excluding 15,904 subjectswhose practice was not linked to the HES database of
hospitalization records. At cohort entry, patients were
71.7 (±12.0) years of age and 49.4% were men, while
65.1% were newly treated with anti-parkinsonian drug.
The mean duration of cohort follow-up was 3.4 (±2.9)
years during which 1,835 patients were diagnosed with
pneumonia, for an overall incidence rate of pneumonia
of 40.9 per 1,000 per year. Among the 1,835 cases of
pneumonia, pneumonia was the principal diagnosis in
45%, while 31% had a diagnosis of acute lower respira-
tory infection, 13% a diagnosis of pneumonitis due to as-
piration of liquids and solids, and for the remaining 11%,
the pneumonias or acute lower respiratory infection
appeared concurrently with a diagnosis of heart failure.
Table 1 describes the characteristics of these cases of
pneumonia and their matched controls. The cases were
diagnosed with pneumonia at 79 years of age, 62% were
male, 57% were newly treated with an anti-Parkinsonian
drug, and over 60% had Parkinson’s disease as the indi-
cation, with controls matched on these characteristics.
For 27%, the indication was not mentioned. As expected,
the pneumonia cases had greater co-morbidity prior to
cohort entry.
After adjustment for differences in the covariates,
current use of pramipexole was not associated with an
increase in the rate of pneumonia compared with no use
(rate ratio (RR) 0.76; 95% confidence interval (CI): 0.57-
1.02) or when compared with current use of all other
dopamine agonists collectively (RR 0.85; 95% CI: 0.62-
1.17), whether ergot-derived or non-ergot-derived
(Table 2). The current use of any dopamine agonist,
compared with non-use, was not associated with an in-
crease in the rate of pneumonia (RR 0.87; 95% CI, 0.75-
1.02). Looking at specific agents, slightly reduced risks
were found for pramipexole (RR 0.76; 95% CI, 0.57-1.02)
and ropinirole (RR 0.76; 95% CI, 0.60-0.97) (Table 3).
Sensitivity analyses showed that the association
observed with pramipexole, compared with other dopa-
mine agonists, remains unchanged when restricting the
analysis to subjects for whom the indication for treat-
ment was Parkinson’s disease (RR 0.75; 95% CI: 0.50-
1.11). Moreover, the results remained similar for the
sub-cohort defined with at least two prescriptions for an
anti-parkinsonian drug, comparing current use of any
dopamine agonist (RR 0.88; 95% CI: 0.75–1.03) and pra-
mipexole (RR 0.75: 95% CI: 0.55-1.01) with non-use.
Results were not affected substantially when changing
the definition of current use from 30 days to either
0 days (RR 0.63; 95% CI: 0.45-0.88), 14 days (RR 0.71;
95% CI: 0.53-0.96), 60 days (RR 0.77; 95% CI: 0.58-1.02),
or 90 days (RR 0.79; 95% CI: 0.60–1.05). To rule out
channeling bias, Table 4 shows the effects of current use
of pramipexole, stratified by history of pneumonia prior
to cohort entry, as well as by use of dopamine agonists,




Age at index date (years; mean ± sd) 79.2 ± 8.0 78.6 ± 7.8








Disease duration at cohort entry among
prevalent users (yrs; mean ± sd)
3.1 ± 2.9 3.1 ± 2.9





Parkinsonian syndrome 127 (6.9) 649
(6.9)
Restless leg syndrome 85 (4.6) 644
(4.6)














Alcohol abuse (%) 104 (5.7) 701
(4.4)













Heart Failure 175 (9.5) 880 (5.2)

















History of prior Pneumonia 127 (6.9) 564
(3.6)














Renal Failure 84 (4.6) 473
(2.8)
Dementia 153 (8.3) 918 (5.5)
Motor Neuron Disease 1 (0.1) 11 (0.1)




















































Barbiturates 0 (0.0) 6 (0.0)
Mood Stabilizers 14 (0.8) 134 (0.8)
Immunosuppressants 5 (0.3) 28 (0.2)




* Percentages weighted by the inverse of the number of controls per cases.
† Percentages among subjects with no missing data in these variables.
{Excluding the 2 weeks prior to the index date.
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period prior to 180 days before the index date. The ef-
fect remained similar when using the more restricted
definition of pneumonia (RR 0.67; 95% CI: 0.43-1.06).Discussion
Using a large population-based cohort of users of anti-
Parkinsonian drugs, we found that the use of pramipexole
Table 2 Crude and adjusted rate ratios of pneumonia associated with current use of pramipexole relative to other
dopamine agonists
Cases Controls Crude Adjusted*
Rate Ratio Rate ratio 95% CI
Number of subjects 1835 16,088
Current use† of (%)
Pramipexole (%) 59 (3.2) 734 (4.6) 0.80 0.85 0.62 – 1.17
All other dopamine agonists (%) 210 (11.4) 2112 (13.1) 1.00 1.00 Reference
Pramipexole (%) 59 (3.2) 734 (4.6) 0.90 0.95 0.68 – 1.35
Non-Ergot-derived dopamine agonists (%) 101 (5.5) 1157 (7.2) 1.00 1.00 Reference
Pramipexole (%) 59 (3.2) 734 (4.6) 0.72 0.75 0.53 – 1.08
Ergot-derived dopamine agonists (%) 109 (5.9) 966 (6.0) 1.00 1.00 Reference
* Adjusted for current use of other anti-parkinsonian drugs, including levodopa, selegiline, rasagiline, COMT inhibitors and amantadine, and all factors listed in
Table 1.
† Current use refers to a prescription ending after or within 30 days prior to the index date.
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pneumonia requiring hospitalization.
Community-acquired pneumonia is common in the
elderly, with an estimated incidence of 15.4 per 1000
persons per year at ages 60–74 years and 34.2 at age
greater than 75 years [14]. Parkinson’s disease has been
associated with a significant increase in deaths from
pneumonia and in particular aspiration pneumonia
[3-5]. Swallowing impairment is a frequent finding in
Parkinson’s disease, occurring in about 50% of patients
[15]. Aspiration pneumonia may develop due to the in-
filtration of foreign materials into the bronchial tree,
usually oral or gastric contents. The effect of dopamin-
ergic treatment on swallowing in Parkinson’s disease has
been little studied and no consistent effect found
[16,17]. It is possible that the slightly reduced risk of
pneumonia observed with current therapy with prami-
pexole and ropinirole might be related to a decrease inTable 3 Crude and adjusted rate ratios of pneumonia associa
relative to non-current use
Cases Contro
Number of subjects 1835 16088
Current use† of:
Any dopamine agonist (%) 269 (14.7) 2,846 (17
Pramipexole (%) 59 (3.2) 734 (4.
Ropinirole (%) 92 (5.0) 1,095 (6.
Cabergoline (%) 57 (3.1) 397 (2.
Pergolide (%) 43 (2.3) 418 (2.
Other dopamine agonists{ (%) 23 (1.3) 234 (1.
* Adjusted for one another, for current use of other anti-Parkinsonian drugs, includi
factors listed in Table 1.
† Current use refers to a prescription ending after or within 30 days prior to the ind
{ Regroups rotigotine, bromocriptine, and lisuride because of low frequencies.aspiration into the bronchial tree. Another explanation
is the presence of residual confounding, although we
adjusted for treatment indication, disease duration and
use of other anti-parkinsonian medications.
This study has strengths and limitations. We
assembled a large population-based cohort of over
13,000 patients observed over 12 years, a size and
follow-up that enabled the identification of a large num-
ber of incident cases of pneumonia and precise estimates
of the risk. Selection bias was avoided by the complete-
ness of the population-based cohort, which also provides
generalizability. The possibility of recall bias in terms of
exposure to dopamine agonists is avoided because the
GPRD uses pre-recorded medication exposure histories.
While we adjusted the risk estimates for several major
confounders, there may have been some residual con-
founding from unmeasured covariates such as disease
severity, as we did not have information on the severityted with current use of the different dopamine agonists
ls Crude Adjusted*
Rate Ratio Rate ratio 95% CI
.7) 0.77 0.87 0.75 – 1.02
6) 0.64 0.76 0.57 – 1.02
8) 0.69 0.76 0.60 – 0.97
5) 1.15 1.28 0.94 – 1.75
6) 0.90 1.06 0.76 – 1.50
5) 0.74 0.77 0.48 – 1.22
ng levodopa, selegiline, rasagiline, COMT inhibitors and amantadine, and all
ex date.
Table 4 Adjusted rate ratios of pneumonia associated with current use of pramipexole relative to non-current use,
stratified by history of pneumonia prior to cohort entry and use of anti- parkinsonian medication prior to the 180-day
period before the index date
Cases Controls Adjusted* P-value for interaction
Rate ratio 95% CI
Number of subjects 1835 16088
History of pneumonia 4/127 23/564 0.66 0.22 – 2.00 0.81
No history of pneumonia 55/1708 711/15524 0.75 0.56 – 1.01
Levodopa use 36/1524 461/13128 0.71 0.49 – 1.01 0.43
No levodopa use 23/311 273/2960 0.90 0.55 – 1.45
Any dopamine agonist use 46/437 602/3993 0.67 0.48 – 0.95 0.44
No dopamine agonist use 13/1398 132/12095 0.89 0.47 – 1.66
Ergot-derived dopamine agonist use 14/258 148/2082 0.69 0.38 – 1.24 0.80
No ergot-derived dopamine agonist use 45/1577 586/14006 0.75 0.54 – 1.04
* Adjusted for current use of other dopamine agonists, other anti-parkinsonian drugs and selected.
factors from Table 1, namely age, duration of APK use, obesity, smoking, alcohol, cerebrovascular, ischemic heart disease, hypertension, heart failure, diabetes,
edema, COPD, asthma, prior pneumonia, lung cancer, other cancer, depression, anemia, renal failure, vaccination (influenza and pneumonia), PPIs, NSAIDs, oral
corticosteroids, other respiratory medications, antibiotics, antipsychotics and antidepressants.
{ Current use refers to a prescription ending after or within 30 days prior to the index date.
{ Previous timing of covariate refers to the period prior to 180 days before the index date.
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the presence of motor complications of medications, for
example. We did adjust for the duration of the disease
using the first prescription of dopaminergic medication
as an indirect proxy for disease severity. Also, the con-
comitant use of other dopaminergic treatments, indicat-
ing a more advanced disease was taken into account. It
is unlikely that such confounding had much effect on
the comparative risks among dopamine agonists, as
there is no evidence that the choice of agent is related to
severity. Despite its size, our study was not sufficiently
large for the stratification needed to study the effects of
dose and duration of pramipexole use.
Conclusion
In summary, the use of pramipexole and of other dopa-
mine agonists, did not appear to increase the risk of
pneumonia in this study population.
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